Internal Medicine, Department of Clinical and Biological Sciences, S. Luigi Hospital, University of Turin, 10043 Turin, Italy.
Endocrine Unit of University Hospital of Messina, University of Messina, 98124 Messina, Italy.
J Clin Endocrinol Metab. 2023 Sep 18;108(10):2517-2525. doi: 10.1210/clinem/dgad199.
Because of the rarity of adrenocortical cancer (ACC), only a few population-based studies are available, and they reported limited details in the characterization of patients and their treatment.
To describe in a nationwide cohort the presentation of patients with ACC, treatment strategies, and potential prognostic factors.
Retrospective analysis of 512 patients with ACC, diagnosed in 12 referral centers in Italy from January 1990 to June 2018.
ACC diagnosed as incidentalomas accounted for overall 38.1% of cases, with a frequency that increases with age and with less aggressive pathological features than symptomatic tumors. Women (60.2%) were younger than men and had smaller tumors, which more frequently secreted hormones. Surgery was mainly done with an open approach (72%), and after surgical resection, 62.7% of patients started adjuvant mitotane therapy. Recurrence after tumor resection occurred in 56.2% of patients. In patients with localized disease, cortisol secretion, ENSAT stage III, Ki67%, and Weiss score were associated with an increased risk of recurrence, whereas margin-free resection, open surgery, and adjuvant mitotane treatment were associated with reduced risk. Death occurred in 38.1% of patients and recurrence-free survival (RFS) predicted overall survival (OS). In localized disease, age, cortisol secretion, Ki67%, ENSAT stage III, and recurrence were associated with increased risk of mortality. ACCs presenting as adrenal incidentalomas showed prolonged RFS and OS.
Our study shows that ACC is a sex-related disease and demonstrates that an incidental presentation is associated with a better outcome. Given the correlation between RFS and OS, RFS may be used as a surrogate endpoint in clinical studies.
由于肾上腺皮质癌(ACC)的罕见性,仅有少数基于人群的研究可用,并且它们在患者特征及其治疗方面的报道细节有限。
在全国性队列中描述 ACC 患者的表现、治疗策略和潜在的预后因素。
回顾性分析了 1990 年 1 月至 2018 年 6 月在意大利 12 个转诊中心诊断的 512 例 ACC 患者。
ACC 作为偶发瘤诊断占所有病例的 38.1%,其发生率随着年龄的增长而增加,并且具有比症状性肿瘤更少侵袭性的病理特征。女性(60.2%)比男性更年轻,肿瘤更小,更常分泌激素。手术主要采用开放方式(72%),在肿瘤切除后,62.7%的患者开始接受辅助米托坦治疗。56.2%的患者在肿瘤切除后复发。在局部疾病患者中,皮质醇分泌、ENSAT 分期 III 期、Ki67%和 Weiss 评分与复发风险增加相关,而无肿瘤切缘、开放手术和辅助米托坦治疗与复发风险降低相关。38.1%的患者死亡,无复发生存(RFS)预测总生存(OS)。在局部疾病中,年龄、皮质醇分泌、Ki67%、ENSAT 分期 III 期和复发与死亡率增加相关。表现为肾上腺偶发瘤的 ACC 显示出延长的 RFS 和 OS。
我们的研究表明,ACC 是一种与性别相关的疾病,并表明偶发表现与更好的结果相关。鉴于 RFS 和 OS 之间的相关性,RFS 可作为临床研究中的替代终点。